阿立哌唑与利培酮治疗精神分裂症的对照研究

目的观察阿立哌唑治疗精神分裂症的临床疗效和安全性。方法将65例精神分裂症患者随机分为阿立哌唑组32例和利培酮组33例。分别采用阿立哌唑和利培酮治疗，疗程8周。采用阳性与阴性症状量表（PANSS）和治疗中出现的症状量表（TESS）于治疗前后评定临床疗效和不良反应。结果两组治疗后的PANSS评分均较治疗前显著降低（P〈0．01）。阿立哌唑组和利培酮组的显效率分别为75．0％和69．7％，总有效率分别为93．8％和90．9％，两组比较无显著性差异（P均〉0．05）。两组TESS均分也无显著性差异（P〉0．05）。结论阿立哌唑治疗精神分裂症疗效肯定，不良反应少。

Control study of aripiprazole and rispeidone in treatment of patients with schizophrenia

Objective To observe the therapeutic effect and safety of aripiprazole in treatment of patients with schizophrenia. Methods 65 patients with schizophrenia were divided randomly into aripiprazole group and rispeidone group, taking aripiprazole and rispeidone respectively for 8 weeks. The positive and negative symptoms scale (PANSS) and treatment emergent symptom scale(TESS) were used to evaluate the efficacy and side effects. Results The score of PANSS of both groups significantly dropped after treatment (P<0.01). The improving rate of aripiprazole group and rispeidone group were 75.0% and 69.7% respectively, the total effectiveness rate were 93.8% and 90.9% respectively, but showed no significant difference between two groups(both P>0.05).The mean score of TESS of both group had no significant difference also(P>0.05).Conclusion Aripiprazole is effective in treatment of patients with schizophrenia with few side effects.